Document:

EX-10.3

 Exhibit 10.3 
 SECOND OMNIBUS AMENDMENT 
 This SECOND OMNIBUS AMENDMENT (this “Second
Amendment”) is made and entered into as of March 5, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). 
 WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September 24, 2011 (the
“Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into an Omnibus Amendment dated as of February 6, 2012 (the “First Amendment”),
amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; 
 WHEREAS, the Securities Purchase
Agreement, as amended by the First Amendment, in Section 8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on
March 5, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; 

WHEREAS, the Bridge Notes dated September 24, 2011 held by the Investors, as amended by the First Amendment, in Section 1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i) March 5, 2012 or (ii) an Event of Default (as defined in the Bridge Notes); 

WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes to extend the
March 5, 2012 date; 
 WHEREAS, the parties also desire to amend other provisions of the Securities Purchase Agreement as
set forth below; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
Securities Purchase Agreement Amendment. The Securities Purchase Agreement, as amended by the First Amendment, is hereby amended as follows: 
 (a) Section 8.01(c) is hereby amended to replace “March 5, 2012” with “March 31, 2012. 
 (b) The following new section is added to ARTICLE V: 

Section 5.16 Advirna Confirmation. The Company shall have received from Advirna written confirmation, in a
form satisfactory to the Investors in their 

 
sole discretion, that the Advirna Amendment remains in full force and effect and that the Company’s rights arising thereunder as of the date of execution remain intact as of the date of such
confirmation. 
 2. Bridge Notes Amendment. The Bridge Notes, as amended by the First Amendment, are hereby amended to
replace references to “March 5, 2012” with “March 31, 2012.” 
 3. Miscellaneous. Capitalized terms
used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement
are incorporated herein by reference. Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President and Chief Executive Officer
	
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President
	
	TANG CAPITAL PARTNERS, LP
		
	By:	 	     /s/ Kevin C. Tang

		 	Kevin C. Tang
		 	Managing Director
	
	RTW INVESTMENTS, LLC
		
	By:	 	     /s/ Roderick Wong

		 	Roderick Wong
		 	Managing Member

 [Signature Page to Second Omnibus Amendment]EX-10.4

 Exhibit 10.4 
 THIRD OMNIBUS AMENDMENT 
 This THIRD OMNIBUS AMENDMENT (this “Third
Amendment”) is made and entered into as of March 30, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). 
 WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September 24, 2011 (the
“Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into an Omnibus Amendment dated as of February 6, 2012 (the “First Amendment”) and a
Second Omnibus Amendment dated as of March 5, 2012 (the “Second Amendment” and, together with the First Amendment, the “Previous Amendments”), amending certain provisions of the Securities Purchase Agreement
and the Bridge Notes; 
 WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in
Section 8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on March 31, 2012, which date may be extended from
time to time by mutual written consent of the Company and the Investors; 
 WHEREAS, the Bridge Notes dated September 24,
2011 held by the Investors, as amended by the First Amendment, in Section 1.1 thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i) March 31, 2012 or (ii) an Event of Default (as defined
in the Bridge Notes); 
 WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the
Bridge Notes to extend the March 31, 2012 date; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Securities Purchase Agreement Amendment. Section 8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace “March 31,
2012” with “April 4, 2012”. 
 2. Bridge Notes Amendment. The Bridge Notes, as amended by the Previous
Amendments, are hereby further amended to replace references to “March 31, 2012” with “April 4, 2012”. 
 3.
Miscellaneous. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article
X of the Securities 

 
Purchase Agreement are incorporated herein by reference. Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant
to Section 10.03 of the Securities Purchase Agreement. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President and Chief Executive Officer
	
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President
	
	TANG CAPITAL PARTNERS, LP
		
	By:	 	     /s/ Kevin C. Tang

		 	Kevin C. Tang
		 	Managing Director
	
	RTW INVESTMENTS, LLC
		
	By:	 	     /s/ Roderick Wong

		 	Roderick Wong
		 	Managing Member

 [Signature Page to Third Omnibus Amendment]EX-10.5

 Exhibit 10.5 
 FOURTH OMNIBUS AMENDMENT 
 This FOURTH OMNIBUS AMENDMENT (this “Fourth
Amendment”) is made and entered into as of April 3, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). 
 WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September 24, 2011 (the
“Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into an Omnibus Amendment dated as of February 6, 2012 (the “First Amendment”), a
Second Omnibus Amendment dated as of March 5, 2012 (the “Second Amendment”) and a Third Omnibus Amendment dated as of March 30, 2012 (the “Third Amendment” and, together with the First Amendment and the
Second Amendment, the “Previous Amendments”), amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; 
 WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in Section 8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if
the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on March 31, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; 

WHEREAS, the Bridge Notes dated September 24, 2011 held by the Investors, as amended by the First Amendment, in Section 1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i) April 4, 2012 or (ii) an Event of Default (as defined in the Bridge Notes); 

WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes to extend the
April 4, 2012 date; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
Securities Purchase Agreement Amendment. Section 8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace “April 4, 2012” with “April 11, 2012”.

 2. Bridge Notes Amendment. The Bridge Notes, as amended by the Previous Amendments, are hereby further amended to
replace references to “April 4, 2012” with “April 11, 2012”. 
 3. Miscellaneous. Capitalized terms
used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as 

 
amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement are incorporated herein by reference. Nothing herein shall constitute a waiver of any
provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President and Chief Executive Officer
	
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President
	
	TANG CAPITAL PARTNERS, LP
		
	By:	 	     /s/ Kevin C. Tang

		 	Kevin C. Tang
		 	Managing Director
	
	RTW INVESTMENTS, LLC
		
	By:	 	     /s/ Roderick Wong

		 	Roderick Wong
		 	Managing Member

 [Signature Page to Fourth Omnibus Amendment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]